Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons

Molecular Cancer Therapeutics

Volumn 3, Issue 4, 2004, Pages 393-402

  van Waardenburg, Robert C A M ^a,c   de Jong, Laurina A ^a   van Delft, Foke ^a   van Eijndhoven, Maria A J ^a   Bohlander, Melanie ^a   Bjornsti, Mary Ann ^c   Brouwer, Jaap ^b   Schellens, Jan H M ^a,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CISPLATIN; CYTARABINE; DNA; DNA TOPOISOMERASE; RAD52 PROTEIN; TOPOTECAN;

ANIMAL CELL; ARTICLE; CELL LINE; CELL TYPE; CONTROLLED STUDY; DNA REPAIR; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; GENETIC CONSERVATION; HOMOLOGOUS RECOMBINATION; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; WILD TYPE; X RAY ANALYSIS; YEAST CELL;

ANIMALS; CAMPTOTHECIN; CELL SURVIVAL; CHO CELLS; CISPLATIN; CRICETINAE; CRICETULUS; CYTARABINE; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENZYME INHIBITORS; RAD52 DNA REPAIR AND RECOMBINATION PROTEIN; RECOMBINATION, GENETIC; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SCHIZOSACCHAROMYCES; X-RAYS;

EID: 4444274233     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Goldwasser F, Valenti M, Torres R, Kohn KW, Pommier Y. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin Cancer Res, 1996;2:687-93.
2. Rowinsky EK, Kaufmann SH, Baker SD, et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol, 1996;14:3074-84.
3. Ma J, Maliepaard M, Nooter K, et al. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol, 1998;41:307-16.
4. Petit C, Sancar A. Nucleotide excision repair: from E. coli to man. Biochimie, 1999;81:15-25.
5. Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature, 2001;411:366-74.
6. Lindahl T, Wood RD. Quality control by DNA repair. Science, 1999; 286:1897-905.
7. Eng W-K, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol, 1988;34:755-60.
8. Nitiss J, Wang JC. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA, 1988;85:7501-5.
9. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol, 2002;3:430-40.
10. Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol, 2001;41:53-77.
11. Kohn KW, Pommier Y. Molecular and biological determinants of the cytotoxic actions of camptothecins. Ann NY Acad Sci, 2000;922:11-26.
12. Reid RJD, Benedetti P, Bjornsti M-A. Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs. Biochim Biophys Acta, 1998;1400:289-300.
13. Doe CL, Ahn JS, Dixon J, Whitby MC. Mus81-Eme1 and Rqh1 involvement in processing stalled and collapsed replication forks. J Biol Chem, 2002;277:32753-9.
14. Vance JR, Wilson TE. Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage. Proc Natl Acad Sci USA, 2002;99:13669-74.
15. McGlynn P, Lloyd RG. Recombinational repair and restart of damaged replication forks. Nat Rev Mol Cell Biol, 2002;3:859-70.
16. Strumberg D, Pilon AA, Smith M, Hickey R, Malkas L, Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol, 2000;20:3977-87.
17. Crul M, van Waardenburg RCAM, Beijnen JH, Schellens JHM. DNA-based drug interactions of cisplatin. Cancer Treat Rev, 2002;28:291-303.
18. Cole RS. Repair of DNA containing interstrand crosslinks in Escherichia coli: sequential excision and recombination. Proc Natl Acad Sci USA, 1973;70:1064-8.
19. Li L, Peterson CA, Lu X, Wei P, Legerski RJ. Interstrand cross-links induce DNA synthesis in damaged and undamaged plasmids in mammalian cell extracts. Mol Cell Biol, 1999;19:5619-30.
20. McHugh PJ, Sones WR, Hartely JA. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol Cell Biol, 2000;20:3425-33.
21. Kuraoka I, Kobertz WR, Ariza RR, Biggerstaff M, Essigmann JM, Wood RD. Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem, 2000;275:26632-6.
22. Pourquier P, Ueng L-M, Kohlhagen G, et al. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem, 1997;272: 7792-6.
23. Pourquier P, Ueng L-M, Fertala J, et al. Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. J Biol Chem, 1999;274:8516-23.
24. Pourquier P, Takebayashi U, Urasaki Y, Gioffere C, Kohlhagen G, Pommier Y. Induction of topoisomerase I cleavage complexes by 1-β-D-arabinofuranosylcytosine (Ara-C) in vitro and in Ara-C-treated cells. Proc Natl Acad Sci USA, 2000;97:1885-90.
25. Paques F, Haber JE. Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol Mol Biol Rev, 1999;63:349-404.
26. Knab AM, Fertala J, Bjornsti M-A. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. J Biol Chem, 1993; 268:22322-30.
27. Fan H-Y, Cheng KK, Klein HL. Mutations in the RNA polymerase II transcription machinery suppress the hyperrecombination mutant hpr1Δ of Saccharomyces cerevisiae. Genetics, 1996;142:749-59.
28. Chou T-C, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst, 1994;86:1517-24.
29. Peters GJ, van der Wilt CL, van Moorsel CJA, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther, 2000;87:227-53.
30. Bjornsti M-A. Cancer therapeutics in yeast. Cancer Cell, 2002;2: 267-73.
31. Kauh EA, Bjornsti M-A. SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I. Proc Natl Acad Sci USA, 1995;92:6299-303.
32. Simon JA, Szankasi P, Nguyen DK, et al. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res, 2000;60:328-33.
33. Bennet CB, Lewis LK, Karthikeyan G, et al. Genes required for ionizing radiation resistance in yeast. Nat Genet, 2001;29:426-34.
34. Grossmann KF, Ward AM, Matkovic ME, Folias AE, Moses RE. S. cerevisiae has three pathways for DNA interstrand crosslink repair. Mutat Res, 2001;487:73-83.
35. Bjornsti M-A, Benedetti P, Viglianti GA, Wang JC. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res, 1989;49:6318-23.
36. Perego P, Zunino F, Carenini N, Giulian F, Spinelli S, Howell SB. Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutants. Mol Pharmacol, 1998;54:213-9.
37. van den Bosch M, Zonneveld JBM, Vreeken K, de Vries FAT, Lohman PHM, Pastink A. Differential expression and requirements for Schizosaccharomyces pombe RAD52 homologs in DNA repair and recombination. Nucleic Acids Res, 2002;30:1316-24.
38. Crul M, van Waardenburg RCAM, Bocxe S, van Eindhoven MAJ, Pluim D, Beijnen JH, Schellens JHM. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol, 2003;65:275-82.
39. de Silva IU, McHugh PJ, Clingen PH, Hartly JA. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res, 2002;30:3848-56.
40. van den Bosch M, Vreeken K, Zonneveld JBM, et al. Characterization of RAD52 homologs in the fission yeast Schizosaccharomyces pombe. Mutat Res, 2001;461:311-23.
41. Sonoda E, Takata M, Yamashita Y, Morrison C, Takeda S. Homologous DNA recombination in vertebrate cells. Proc Natl Acad Sci USA, 2001;98:8388-94.
42. Miyamoto S, Huang TT, Wuerzberger-Davis S, et al. Cellular and molecular responses to topoisomerase I poisons: exploiting synergy for improved radiotherapy. Ann NY Acad Sci, 2000;922:274-92.
43. Nair JS, Kancherla R, Seiter K, Traganos F, Tse-Dinh Y-C. Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia: correlation of clinical and cell culture studies. Ann NY Acad Sci, 2000; 922:326-9.
44. Malkova A, Ivanov EL, Haber JE. Double-strand break repair in the absence of RAD51 in yeast: a possible role for break-induced DNA replication. Proc Natl Acad Sci USA, 1996;93:7131 -6.
45. Ivanov EL, Sugawara N, Fishman-Lobell J, Haber JE. Genetic requirements for the single-strand annealing pathway of double-strand break repair in Saccharomyces cerevisiae. Genetics, 1996;142: 693-704.
46. Dronkert MLG, Beverloo HB, Johnson RD, Hoeijmakers JHJ, Jasin M, Kanaar R. Mouse Rad54 affects DNA double-strand break repair and sister chromatid exchange. Mol Cell Biol, 2000;20:3147-56.
47. Middlemas DS, Stewart CF, Kirstein MN, et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res, 2000;6:998-1007.
48. Verhage RA, van der Putte P, Brouwer J. Repair of rDNA in Saccharomyces cerevisiae: RAD4-independent strand-specific nucleotide excision repair of RNA polymerase I transcribed genes. Nucleic Acids Res, 1996;24:1020-5.